Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

Lilly shares are up about 5% this year. Compared with its peers, the drugmaker has been more insulated from drug price ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly and Company and Walmart Inc. announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect. Zepbound ...

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

The MMA rebrand involves a clear mission, new visual identity, modernised brand architecture, and continued investment in ...

RFK Jr. adds to the Tylenol debate; Lilly partners with Walmart for Zepbound; Trump administration offers draft biologics framework.

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

ETC 6 Meridian Mega Cap Equity ETF offers defensive, value-tilted portfolio focused on high-quality, large-cap US companies.

Eli Lilly partners with NVIDIA to build a powerful AI supercomputer and teams up with Walmart to expand affordable Zepbound access nationwide.

Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant's weight loss drug Zepbound, allowing U.S.